NLS Agreement

Infex Therapeutics has signed an exclusive license agreement for the Indian market with Indian pharmaceutical company Venus Remedies for the clinical development of its metallo-beta-lactamase-inhibitor MET-X, targeting Gram-negative Enterobacterales.

“We are thrilled to announce this strategic partnership with a top-tier medical school in clinical and radiological research. This is a critical step toward our vision of developing multiple products within data quality and liver disease management,” says Gerald Pötzsch, CEO of ContextVision.

A new agreement has been signed by Norwegian Minister of Health Jan Christian Vestre and German State Secretary Edgar Franke.

Orexo has announced that rights to future transaction proceeds and royalty on future net revenues for the drug candidate vipoglanstat (OX-MPI), have been converted to shares in Gesynta Pharma.

This agreement grants Synthego a global license to manufacture and distribute AstraZeneca's novel CRISPR gene editing enzyme, eSpOT-ON, recently published as engineered ePsCas9, to the worldwide research community.

Novo Nordisk and Valo Health have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s human dataset and computation powered by artificial intelligence (AI).